Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.14 is 1760% above its 5-year average of 0.01, near the low end of its 5-year range (-0.03–1.49).
As of the fiscal period ended Friday, July 31, 2026. 58.32% below its 12-month average of 0.33.
Reported quarterly debt to equity ratio; no daily interpolation. Q3 FY2026 (2026-07-31): 0.14.
DEBT TO EQUITY RATIO
0.14
DEBT TO EQUITY RATIO AVG TTM
0.33
DEBT TO EQUITY RATIO AVG 3Y
0.01
DEBT TO EQUITY RATIO AVG 5Y
0.01
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-58.32%
CURRENT VS 3Y AVG
+1170.92%
CURRENT VS 5Y AVG
+1759.96%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 470 covered companies
CURRENT VS SECTOR MEDIAN
-0.82%
vs the sector median at left
Clearmind Medicine Inc.
Market Cap
$1.09M
Debt to Equity Ratio
0.14
TTM Avg
0.33
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$1.11M
Debt to Equity Ratio
0.13
TTM Avg
0.30
3Y Avg
0.57
5Y Avg
0.57
Market Cap
$1.03M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$1.18M
Debt to Equity Ratio
N/A
TTM Avg
0.05
3Y Avg
0.05
5Y Avg
0.05
Market Cap
$893920.00
Debt to Equity Ratio
N/A
TTM Avg
0.01
3Y Avg
0.08
5Y Avg
0.06
Market Cap
$867353.00
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$883067.00
Debt to Equity Ratio
0.00
TTM Avg
0.07
3Y Avg
0.05
5Y Avg
0.04
Market Cap
$797661.00
Debt to Equity Ratio
0.01
TTM Avg
0.03
3Y Avg
0.06
5Y Avg
0.04
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Clearmind Medicine Inc. (CMND) | $1.09M | 0.14 | 0.33 | 0.01 | 0.01 |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.11M | 0.13 | 0.30 | 0.57 | 0.57 |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.03M | 0.00 | 0.00 | 0.00 | 0.00 |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.18M | N/A | 0.05 | 0.05 | 0.05 |
| IM Cannabis Corp. (IMCC)vs › | $1.21M | N/A | 2.19 | 1.26 | 0.86 |
| GlucoTrack, Inc. (GCTK)vs › | $893920.00 | N/A | 0.01 | 0.08 | 0.06 |
| Bone Biologics Corporation (BBLG)vs › | $867353.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Decoy Therapeutics Inc. (DCOY)vs › | $883067.00 | 0.00 | 0.07 | 0.05 | 0.04 |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $797661.00 | 0.01 | 0.03 | 0.06 | 0.04 |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.38M | 0.01 | 0.02 | 0.01 | 0.01 |
Debt/Equity
0.14
Current Ratio
4.31
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-07-31 | 0.14 |
| 2026-04-30 | 0.01 |
| 2026-01-31 | 0.00 |
| 2025-10-31 | 1.49 |
| 2025-07-31 | 0.03 |
| 2025-04-30 | 0.02 |
| 2025-01-31 | 0.02 |
| 2024-10-31 | 0.02 |
| 2024-07-31 | 0.02 |
| 2024-04-30 | 0.00 |
| 2024-01-31 | 0.02 |
| 2023-10-31 | 0.00 |
| 2023-07-31 | 0.00 |
| 2023-04-30 | 0.00 |
| 2023-01-31 | 0.01 |
| 2022-10-31 | -0.03 |
| 2022-07-31 | 0.13 |
| 2022-04-30 | 0.00 |
| 2022-01-31 | 0.00 |
| 2021-10-31 | 0.00 |
| 2021-07-31 | 0.00 |
| 2021-04-30 | 0.00 |
| 2021-01-31 | 0.00 |
| 2020-10-31 | 0.00 |
| 2020-07-31 | 0.00 |
| 2020-04-30 | 0.00 |
| 2020-01-31 | 0.00 |
| 2019-10-31 | 0.00 |
| 2019-07-31 | 0.00 |
| 2019-04-30 | 0.00 |
| 2019-01-31 | 0.00 |
| 2018-10-31 | 0.00 |
| 2018-07-31 | 0.00 |
| 2018-04-30 | 0.00 |
| 2018-01-31 | 0.00 |
| 2017-10-31 | 0.00 |
